sglt2 inhibitors vs glp-1 vs. Agonists to Treat the Heart, the Kidneys and the Brain SGLT-2 inhibitors or GLP-1 receptor

Research on GLP-1 medications shows that steady-state concentrations produce the most predictable outcomes for weight loss and blood sugar regulation

High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis

The difference is the delivery device, since some products use an autoinjector pen while compounded semaglutide uses a vial and syringe

Understanding GLP-1 Therapy as a Safer Weight Loss Option GLP-1 receptor agonists like semaglutide and tirzepatide have demonstrated sustained weight loss of 1522% of body weight in clinical trials, achieved without the stimulant side effects of phentermine

In a primary care setting like Centra Internal Medicine, the initial phase involves monthly follow-ups during the dose-escalation period